Insider buying last 90 days
No open-market insider purchases were filed for TXG in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
10x Genomics reported third-quarter 2026 results this week, with revenue beating estimates and a per-share loss of $0.15 versus a year-ago loss of $0.22. The company raised its full-year 2026 sales guidance to $625 million-$635 million, up from $610 million-$630 million and above the consensus estimate of $619.854 million, citing strong demand for its Atera spatial biology platform, which nearly all of the top 20 biopharma companies have now purchased or used via Catalyst Research Services, which booked over 100 customers in its first five months. The company also launched Sentira Single Cell, a Claude-powered AI tool aimed at simplifying data analysis. Despite the raised guidance, shares reacted with a last-earnings move of -12.2%.
TXG closed at $65.05, up 9.7% on the day, with the stock sitting between its 50-day average of $74.02 and 200-day average of $41.80. The one-month return stands at -19.3%, while six-month and one-year returns remain sharply positive at 217.3% and 400.4%. The GekkoIndex reads 62.3, placing the stock in the Accumulation zone, down 2.2 over the past five readings. Price sits 13.7% below Gekko Fair Value of $75.37.
The next earnings date falls on 11 February 2027, 93 days out, beyond a typical 20-trading-day holding window. Over the last 30 days, one unusual options signal appeared, with call premium of $2,178,765 and no put premium recorded. One billionaire holder and one trailblazer holder are noted. Analyst coverage spans 15 firms, with 5 at buy and 10 at hold, and a consensus target of $77.50, implying 19.1% upside. Seasonally, the next 20 trading days have averaged a 4.5% gain over 5 years, rising in 3 of those years.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
10x Genomics scores 4 supportive, 2 mixed and 0 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive2 mixed0 headwinds
Averages disagree
Close $58.19 sits between the 50-day ($73.92) and 200-day ($42.58) averages, or the averages disagree.
See the chart64, Accumulation
Reading 64 is in the Accumulation zone.
See the GekkoIndex18.7% below
Price is 18.7% below Gekko Fair Value (more than 5% below).
See fair valueLeans bullish
Last 30 days: 1 unusual options signal.
See smart moneyReports in 88 days
Next report Feb 11, 2027, 88 days away — outside a typical 20-trading-day hold.
See earnings+0.9% on average
From this point in the calendar, the next 20 trading days averaged +0.9% over 5 years, rising in 2 of them.
See seasonalityA description of current data, not a recommendation. How this page works
10x Genomics closed at $58.19 on Nov 13, 2026, +248.7% over the past year, inside a 52-week range of $15.12 to $102.81.
Use the left and right arrow keys to read daily values.
Put TXG on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
10x Genomics builds tools that let scientists study biology at the level of individual cells and within tissue samples. Its equipment, supplies and software are used to examine gene activity, immune cell behavior, and the physical structure of DNA, giving researchers a detailed picture of how biological systems function. The company is particularly known for its Chromium and Chromium Connect instruments, which work alongside microfluidic chips, slides and reagents to support this kind of single-cell analysis.
Much of its product range centers on single-cell applications built around the Chromium platforms, covering gene expression, immune profiling, chromatin accessibility, and combined measurement of genetic and epigenetic activity across large numbers of cells at once. The company also produces a spatial gene expression solution called Visium, which maps where gene activity occurs within tissue sections and can be paired with immunofluorescence to detect proteins alongside gene expression. Customers span academic institutions, government bodies, and biopharmaceutical and biotechnology organizations, and the company's reach extends across North America, Europe, the Middle East, Africa, China and the Asia Pacific.
10x Genomics is headquartered in Pleasanton, California, and traces its founding to 2012, having operated for a time under the name 10X Technologies before adopting its current name. Its shares are listed on the NASDAQ under the ticker TXG.
10x Genomics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 64, in the Accumulation zone, down 1.4 points over five sessions.
Down 1.4 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 88 | −0.3% | −6.1% | ||
| Accumulation (current zone) | 208 | −0.2% | +2.1% | ||
| Neutral | 358 | +1.9% | +7.0% | ||
| Distribution | 47 | −2.2% | −0.4% | ||
| Selling | 1 | Too few readings yet | |||
Average TXG share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
10x Genomics trades 18.7% below Gekko Fair Value of $71.61, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what 10x Genomics shares are worth, recalculated every trading day.
$71.61
Gekko Fair Value, Nov 14, 2026
18.7% Undervalued
At the end of Aug 2026 the price was 26.9% above the estimate.
No open-market insider purchases were filed for 10x Genomics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for TXG in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in TXG were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
10x Genomics has been buying back its own shares.
From company filings.
1signal, 100% of the flagged premium in calls.
Latest: Bullish flow on Oct 29, $2.18M in unusual premium.
2of the funds Gekko tracks hold TXG.
10x Genomics reports on Feb 11, 2027, after the close (88 days away), and beat the EPS estimate in 6 of its last 8 reports.
Feb 11, 2027
Expected after the close, 88 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Nov 5, 2026 | −$0.15 est −$0.27 | $150.7M est $148.0M | −12.2% |
| Aug 6, 2026 | −$0.14 est −$0.23 | $151.0M est $146.7M | +9.6% |
| May 7, 2026 | −$0.10 est −$0.29 | $150.8M est $146.4M | −5.0% |
| Feb 12, 2026 | −$0.13 est −$0.19 | $166.0M est $159.7M | −5.4% |
| Nov 6, 2025 | −$0.22 est −$0.07 | $149.0M est $142.5M | +13.0% |
| Aug 7, 2025 | $0.28 est −$0.35 | $172.9M est $139.5M | −2.9% |
| May 8, 2025 | −$0.36 est −$0.45 | $154.9M est $145.3M | +5.5% |
| Feb 12, 2025 | −$0.40 est −$0.29 | $165.0M est $165.0M | +1.0% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for 10x Genomics is $68.14, +17.1% from the last close, from 15 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 15 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 11 | Stephens | $65 | +11.7% |
| Nov 9 | Barclays | $70 | +20.3% |
| Nov 9 | UBS | $61 | +4.8% |
| Nov 9 | J.P. Morgan | $65 | +11.7% |
| Nov 6 | TD Cowen | $55 | −5.5% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, 10x Genomics averaged +0.9% across the last 5 years, rising in 2 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −0.7% | 2 of 5 |
| Next 10 trading days | +2.6% | 3 of 5 |
| Next 15 trading days | +2.2% | 3 of 5 |
| Next 20 trading days | +0.9% | 2 of 5 |
| Next 30 trading days | +3.5% | 2 of 5 |
For scale, TXG’s typical 20-trading-day move in either direction is about 13.4%.
10x Genomics’s market cap is $7.00B and revenue of $618.6M over the last twelve months.
6 headlines about 10x Genomics from the past week, newest first, each linking to the publisher.
10x Genomics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 19.9% below |
| GILDGilead Sciences | Neutral | 11.7% above |
| MRNAModerna | Neutral | 21.1% above |
| NTRANatera | Accumulation | 18.6% below |
| IQVIQVIA | Accumulation | 5.0% above |
| UTHRUnited Therapeutics | Neutral | 11.2% below |
A peer links to its own page where one exists.
10x Genomics’s market cap is $7.00B at the Nov 13, 2026 close of $58.19, with 121.5M shares outstanding.
The consensus analyst 12-month price target for 10x Genomics is $68.14, +17.1% from the last close. Of the 15 firms that rated the stock in the last 90 days, 5 rate it a buy, 10 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate 10x Genomics is undervalued: the Nov 13, 2026 close of $58.19 is 18.7% below Gekko Fair Value of $71.61. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
10x Genomics is expected to report on Feb 11, 2027, after the market closes (88 days away). Analysts expect earnings of −$0.18 per share on revenue of $177.7M. 10x Genomics beat the earnings estimate in 6 of its last 8 reports, moving 6.8% on average across the report.
10x Genomics’s 52-week high is $102.81 and its 52-week low is $15.12; it closed at $58.19 on Nov 13, 2026, +248.7% over the past year. Over the last five years the shares peaked at $167.49 on Nov 15, 2021.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (gekkoindex, fair value, smart money and earnings risk), 2 as mixed (trend and seasonality). The checklist is a description of current data, not a recommendation.
Gekko flagged 1 unusual options signal in 10x Genomics over the last 30 days, with $2.18M of flagged premium in calls and $0 in puts. The latest, bullish flow, was on Oct 29, 2026 with $2.18M in unusual premium. The signal-by-signal table is in Gekko.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.